Angiogenesis and the heart.
The incidence of cardiovascular disease is increasing worldwide. Despite many new developments in 60(th) medical and surgical specialities, a substantial number of cardiac patients are not suitable candidates for one of the current treatment options. This "no-option" subgroup of patients is a driving influence in the rapidly developing field of angiogenesis. In this review, we discuss the different modalities of treatment being tried for these patients and the patents which have been filed to improve cardiac angiogenesis.
Sharma
Shree G
SG
Department of Pathology, University of Arkansas, Arkansas, USA. drshreegopal@gmail.com
Nanda
Sudip
S
Longo
Santo
S
D043925:Angiogenesis Inducing Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005346:Fibroblast Growth Factors / Q000235:genetics / Q000502:physiology; D015316:Genetic Therapy; D006331:Heart Diseases / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D033581:Stem Cell Transplantation; D042442:Vascular Endothelial Growth Factors / Q000235:genetics / Q000502:physiology
D043925:Angiogenesis Inducing Agents; D042442:Vascular Endothelial Growth Factors; D005346:Fibroblast Growth Factors